Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4

MT Newswires Live

Oct 16

Citius Pharmaceuticals' (CTXR) oncology-focused unit Citius Oncology (CTOR) said Thursday that it has signed an exclusive agreement with Eversana to support the planned US launch of the cutaneous T-cell lymphoma therapy Lymphir in Q4.

Citius Oncology said Eversana will be its exclusive commercialization partner under the master services agreement, providing pre- and post-launch operations services such as medical information, revenue cycle management, and data and analytics.

Shares of Citius Oncology were up 26% in recent trading on Thursday, while those of Citius Pharmaceuticals were up 34%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2575773744"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575773744\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575773744?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-16 21:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575773744","market":"hk","top_or_hot":-1,"title":"Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4","media":"MT Newswires Live","content":"<html><body><p> Citius Pharmaceuticals' (CTXR) oncology-focused unit <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> (CTOR) said Thursday that it has signed an exclusive agreement with Eversana to support the planned US launch of the cutaneous T-cell lymphoma therapy Lymphir in Q4.</p><p>Citius Oncology said Eversana will be its exclusive commercialization partner under the master services agreement, providing pre- and post-launch operations services such as medical information, revenue cycle management, and data and analytics.</p><p>Shares of Citius Oncology were up 26% in recent trading on Thursday, while those of Citius Pharmaceuticals were up 34%.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCitius Oncology Says Commercialization Deal Signed With Eversana for Planned Launch of Lymphir in Q4\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-16 21:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Citius Pharmaceuticals' (CTXR) oncology-focused unit <a href=\"https://laohu8.com/S/CTOR\">Citius Oncology</a> (CTOR) said Thursday that it has signed an exclusive agreement with Eversana to support the planned US launch of the cutaneous T-cell lymphoma therapy Lymphir in Q4.</p><p>Citius Oncology said Eversana will be its exclusive commercialization partner under the master services agreement, providing pre- and post-launch operations services such as medical information, revenue cycle management, and data and analytics.</p><p>Shares of Citius Oncology were up 26% in recent trading on Thursday, while those of Citius Pharmaceuticals were up 34%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2575773744","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575773744","pubTimestamp":1760621807,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Citius Pharmaceuticals'  oncology-focused unit Citius Oncology  said Thursday that it has signed an exclusive agreement with Eversana to support the planned US launch of the cutaneous T-cell lymphoma therapy Lymphir in Q4.Citius Oncology said Eversana will be its exclusive commercialization partner under the master services agreement, providing pre- and post-launch operations services such as medical information, revenue cycle management, and data and analytics.Shares of Citius Oncology were up 26% in recent trading on Thursday, while those of Citius Pharmaceuticals were up 34%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4007":"制药","CTOR":"CITIUS ONCOLOGY INC","CTXR":"Citius Pharmaceuticals, Inc."},"translate_title":"Citius Oncology表示与Eversana签署商业化协议，计划于第四季度推出Lymphir","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTXR":1,"CTOR":1},"content_text":"Citius Pharmaceuticals' (CTXR) oncology-focused unit Citius Oncology (CTOR) said Thursday that it has signed an exclusive agreement with Eversana to support the planned US launch of the cutaneous T-cell lymphoma therapy Lymphir in Q4.Citius Oncology said Eversana will be its exclusive commercialization partner under the master services agreement, providing pre- and post-launch operations services such as medical information, revenue cycle management, and data and analytics.Shares of Citius Oncology were up 26% in recent trading on Thursday, while those of Citius Pharmaceuticals were up 34%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}